A COX-2 selective NSAID, namely celecoxib, has also shown good antiamnestic and anti-inflammatory results in in vivo studies utilizing the soluble Aβ-induced AD model, and has been qualified for a clinical trial for the prevention of AD [89,93]. This evidence concerns the gene PTGS2 and Alzheimer disease.